Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

NCT05490030 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Hepatic Impairment

Interventions

DRUG: TNO155

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]